Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Exelixis Inc (EXEL)

Healthcare Biotechnology

53.00 $

-5.3% vs. previous close

Closing price · As of: 31. Jul 2026

Exelixis Inc (EXEL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 2,844 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow

Annual Quarterly

All figures in millions of USD.

Balance Sheet EXEL
Tick rows to compare them in a chart (up to 4)	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	328	332	598	655	1,422	1,886	2,137	2,616	3,071	2,942	2,948	2,844
Current Assets	167	179	471	485	897	1,011	1,445	1,835	1,619	1,318	1,468	1,443
Cash	80	142	152	183	315	267	319	647	501	263	217	482
Cash & Short-Term Investments	144	167	420	388	693	852	1,207	1,467	1,308	995	1,111	1,059
Receivables	4.9	5.2	40	81	179	119	161	283	215	237	265	287
Inventory	2.4	2.6	3.3	6.7	9.8	13	21	27	33	17	22	22
Property, Plant & Equipment	2.4	1.4	2.1	26	57	49	67	149	111	–	–	–
Goodwill	64	64	64	64	64	64	64	64	64	64	64	64
Intangible Assets	64	64	64	64	–	–	–	–	–	–	–	–
Total Liabilities	443	437	508	370	135	200	258	406	583	678	703	683
Current Liabilities	172	52	271	115	105	143	205	338	324	394	404	406
Short-Term Debt	99	418	189	57	57	2.7	3.0	8.7	18	26	25	–
Accounts Payable	6.4	6.4	6.6	9.6	11	12	24	24	33	34	38	30
Long-Term Debt	262	381	0.0	0.4	12	–	–	–	–	–	–	–
Shareholders' Equity	-115	-104	89	285	1,287	1,686	1,879	2,211	2,488	2,264	2,244	2,161
Retained Earnings	-1,767	-1,937	-1,983	-1,829	-880	-559	-448	-217	-34	-173	-99	-77
Shares Outstanding	194	209	251	312	313	315	318	322	325	321	296	282

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Cookie settings